BTK and B-cell chronic lymphocytic leukemia: While most patients respond to targeted therapies directed at BTK or BCL-2 with little prejudice in response to sequence of administration, 15.5% of treatment naïve patients have been reported to develop refractory disease, justifying the need for novel therapies for refractory CLL [6–8].